Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates

Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates
  • Viatris Inc's VTRS Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence of glass particles in a syringe.
  • The lot was manufactured by Italfarmaco SpA, Italy, and was distributed by Mylan Institutional LLC in the U.S. between January 11 and June 21, 2022.
  • Also read: Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label.
  • Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients. 
  • It is also indicated for the symptomatic treatment of patients with metastatic carcinoid tumors, where it suppresses or inhibits severe diarrhea and flushing episodes.
  • Intravenous administration of a solution containing particulate matter could lead to events including local irritation or swelling, vasculitis/phlebitis, allergy, and microvascular obstruction. 
  • No reports of adverse reactions associated with this lot have been received to date.
  • Price Action: VTRS shares are up 1.89% at $9.97 on the last check Wednesday.
Posted In: BriefsBiotechNewsHealth CareFDAGeneral